Our work focuses on building in vitro platforms from human iPSCs to make drug discovery and neurotherapeutic research more predictive and efficient.
Founded in 2011 as a spin-off from the University of Geneva, Neurix has grown into a leading innovator in neuroscience research. Backed by over a decade of expertise and significant European research funding, we specialize in creating advanced human 3D cellular models to study neurodegenerative diseases and other brain disorders.
Our team brings together dedicated professionals with diverse expertise in neuroscience, stem cell technology, and drug discovery. Together, we are committed to bridging the gap between research and clinical application, helping our clients achieve breakthroughs with confidence and precision.
At Neurix, collaboration is at the heart of everything we do. We are proud to partner with researchers and organizations worldwide to drive innovation and make meaningful progress in understanding and treating brain diseases.
After studying stem cells at the Imperial College London, Nikolay gained valuable finance experience at UBS and J.P.Morgan. Nikolay is involved with numerous pharmaceutical startups and has vast contacts in the banking, biotechnology and pharmaceuticals domains. He provides grounded strategy and forward thinking for the development and success of Neurix.
Karl-Heinz is Professor of Medicine at the Faculty of Medicine & University Hospitals of Geneva, as well as honorary professor at the Bejing Hospital, China. Karl-Heinz has been actively involved in inflammation research. Since 1998, he focused his research further on mechanisms of aging and treatment of age-associated diseases. He is an elected member of the Swiss Academy of Medical Sciences, the American Society for Clinical Investigation, and founder of 6 startups.
Beat is a Professor Emeritus in the Department of Pathology & Immunology at the University of Geneva, where he was previously Head of Department. His continued research interests are in the pathology of leukocyte migration in inflammatory diseases & tumor angiogenesis, as well as in drug development. He has also held roles as President of the Swiss Society Allergology & Immunology, & European Society of Microcirculation. He has over 180 publications & patents.
Carla Faria is a PhD-trained immuno-oncologist with experience in stem cell biology, 3D modeling, and personalized medicine. With a strong academic foundation, she has led translational cancer research projects across Europe. At Neurix SA, she serves as an R&D Scientist, where she develops advanced human iPSC-derived brain organoid models to study neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and glioblastoma.
Aurore Bugi is a biotechnology researcher with broad experience in molecular and stem cell biology. She previously worked at Institute for Stem Cell Therapy and Exploration of Monogenic Diseases, France, where she contributed to stem cell therapy program for Huntington’s Disease. She developed protocols for deriving human and monkey pluripotent stem cells and differentiating them into striatal progenitors and neurons. She then joined University of Geneva and later Neurix, currently developing 3D in vitro models of neurodegenerative diseases.
Margareta brings a strong combination of business development expertise and scientific training in gene therapy and neuroscience. She completed her MSc at Imperial College London with a focus on gene therapy, worked as a project manager in a U.S.-based biotech startup developing gene therapies for aging, and earned her PhD in Switzerland using CRISPR-Cas9 approaches in neurodegenerative diseases. At Neurix, she drives strategic partnerships, growth initiatives, and market positioning, ensuring that science is translated into trusted solutions.
Gael is a neuroscientist in neurodegenerative diseases and translational neuroscience. He completed a PhD in cell signaling and pharmacology at the Institute of Functional Genomics in Montpellier, followed by postdoctoral research at Mount Sinai Hospital in New York on Alzheimer’s Disease mechanisms. He later held senior roles at the Interdisciplinary Institute for Neurosciences in Bordeaux and the Wyss Center in Geneva. At Neurix, Gael oversees scientific strategy, R&D programs, and partnerships, focusing on patient-derived brain organoid models for neurological disorders.
